Navigation Links
Shire to present ADHD treatments scientific data at American Psychiatric Assoc. Meeting
Date:5/1/2008

PHILADELPHIA May 1, 2008 Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention Deficit Hyperactivity Disorder (ADHD) treatments, lisdexamfetamine dimesylate, methylphenidate transdermal system and the investigational non-stimulant treatment under FDA review, guanfacine extended release, at the American Psychiatric Association (APA) annual meeting to be held May 3rd to 8th in Washington, D.C.

Shire is committed to the advancement of ADHD research, and we are pleased to be presenting the efficacy and safety results from several studies of our ADHD treatments, said Gwendolyn Niebler, Vice President of Global Medical Affairs at Shire. We believe the physician community will find the lisdexamfetamine dimesylate, methylphenidate transdermal system and guanfacine extended release study findings to be presented at APA a relevant contribution to the growing body of research on our ADHD treatment options.

A summary of the key scientific presentations is provided below. Information about these data presentations mentioned in this release is embargoed until the respective presentation sessions have taken place at the meeting.

Lisdexamfetamine Dimesylate:
May 7, 2008; 12:00 p.m. ET
Lisdexamfetamine Dimesylate Treatment in Children Diagnosed with ADHD: Parental Impressions and Experiences
APA Poster Presentation # NR6-025

May 8, 2008; 11:00 a.m. ET
Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults with ADHD
APA Oral Presentation Session # 28

Methylphenidate Transdermal System:
May 7, 2008; 12:00 p.m. ET
Long-Term Treatment Effects of the Methylphenidate Transdermal System in Boys and Girls with ADHD
APA Poster Presentation # NR6-018

Guanfacine Extended Release:
May 7, 2008; 12:00 p.m. ET
Guanfacine Extended Release: Duration of Effect in Children
'/>"/>

Contact: Lucia Lodato
212-601-8037
Porter Novelli
Source:Eurekalert

Page: 1 2

Related medicine news :

1. AUDIO from Medialink and Shire: What It Means to be an Adult With ADHD
2. Shire Launches Patient Education Forums on Better Managing the Challenges of Ulcerative Colitis
3. VIDEO from Medialink and Shire plc: Rare Diseases Must Be Top of the Health Agenda
4. New Hampshire AIDS Group Calls on Huckabee to Disavow His 1992 Statement
5. Shire to Present New Scientific Data on its ADHD Treatments at a Major Psychiatric Meeting
6. New Hampshire: 1st in the Nation Primary State Takes a Stand on E-Prescribing
7. Families Invited to Celebrate Shire Day at Boston Childrens Museum
8. URAC CEO Testifies Before New Hampshire Legislators Regarding New URAC Standards for Pharmacy Benefit Management
9. Exciting New Plan from John Edwards on AIDS; Plan is Bold and Achievable, say New Hampshire Activists
10. Haemacure to Present at the BioFinance 2008 Conference to be held at the Toronto Marriott Eaton Centre, May 6 - 8, 2008
11. Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2014)... innovative tool that captures heretofore hidden ways that cells ... protein that makes breast cancer cells more likely to ... cancer,s spread in part by blocking two other proteins ... suggests these two disease processes could have unexpected ties. ... 10 issue of Nature , points to the ...
(Date:7/9/2014)... in Russia might contribute to HIV transmission and ... researchers from Boston University Schools of Medicine and ... State University, sought to discover the effect police ... cohort of HIV-positive people with lifetime of injection ... police were more likely to share needlesincreasing HIV ...
(Date:7/9/2014)... YORK (July 8, 2014) Researchers from Montefiore ... of Medicine of Yeshiva University will present new ... held July 12 July 17 in Copenhagen, Denmark. ... that could prompt transition from cognitive normality to mild ... the Einstein Aging Study , established in 1980 ...
(Date:7/9/2014)... most important organs in the human body. Its job ... this is its synthesis function and that ... is its detoxification function. Lack of exercise and too ... liver. The resulting diseased cells can lead to inflammations, ... According to the German Liver Foundation, over five million ...
(Date:7/9/2014)... Qubec City, July 9, 2014 A study published ... Yves De Koninck and Robert Bonin, two researchers at ... pain hypersensitivity using a new method that involves rekindling ... discovery could lead to novel means to alleviate chronic ... at Universit Laval and Institut universitaire en sant mentale ...
Breaking Medicine News(10 mins):Health News:Protein pushes breast cancer cells to metastasize 2Health News:Protein pushes breast cancer cells to metastasize 3Health News:BU researchers relate arrests with HIV risk environment 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 3Health News:Telemedicine for patients with chronic liver diseases 2Health News:Telemedicine for patients with chronic liver diseases 3Health News:Discovery of a new means to erase pain 2
... screening to identify lung tumors likely to respond ... drugs as first-line treatment rather than after standard ... Massachusetts General Hospital Cancer Center investigators found that ... for non-small-cell-lung-cancer (NSCLC), additional research is required before ...
... the ... chance to change people,s lives, OTTAWA, May 20 ... for new ways to make the most of their,time, especially ... independent marketing opportunities provided by,Melaleuca, The Wellness Company(R)., One ...
... May 20 Wednesday, May 21, 2008,Easter Seals Greater ... Mary Landrieu and Capital One for,their efforts on behalf ... Awards Benefit will be held at the JW Marriott ... and dinner at 7:00,pm. Gordon Peterson of WJLA TV ...
... per patient , , TUESDAY, May 20 (HealthDay News) ... latent tuberculosis saves time, money and lives, new research ... of four months of Rifampin instead of the current ... health-care system," lead analyst Anne Aspler, of the respiratory ...
... May 20 The retiring baby boomers,have challenged ... Moreover, the multi-generational workforce is challenging,companies across all ... to define a new type of leader., ... new thinking,around leadership models, discover fast-acting tactics and ...
... idiopathic pulmonary fibrosis (IPF) may have a new treatment ... Phase III, double-blind, placebo-controlled clinical trial, the investigators discovered ... progression of IPF, reducing the loss of lung capacity. ... Societys 2008 International Conference in Toronto on Tuesday, May ...
Cached Medicine News:Health News:Determining genetic signature of lung tumors can help guide treatment 2Health News:Determining genetic signature of lung tumors can help guide treatment 3Health News:Lucrative Sales Opportunities Abound With Melaleuca, The Wellness Company(R) 2Health News:New Latent TB Drug Saves Lives, Money 2Health News:Fortune 500s to Convene in Florida, Sharing Insights & Best Practices for Developing Tomorrow's Leaders 2Health News:New treatment gives hope for pulmonary fibrosis patients 2
(Date:1/15/2014)... Jan. 15, 2014  According to Millennium Research Group ... intelligence, the United States ... markets will expand moderately through 2022, with embolization ... particular, increasing interest in drug-eluting beads (DEBs) and ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... market research report is available in ... Global Markets and Technologies for Advanced ... Routes of Administration ...
(Date:1/14/2014)... , Jan. 14, 2014 InformEx, North ... sellers of high-value chemistry, will hold the 30 th ... Beach Convention Center from January 21-24. ... attendees from top pharmaceutical, fine chemical and specialty chemical companies ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... Reportlinker.com announces that a new market research report ... Merger and Acquisition Terms and Agreements in ... http://www.reportlinker.com/p0306576/Merger-and-Acquisition-Terms-and-Agreements-in-Pharma-Biotech-and-Diagnostics-4th-edition.html ... analysis of how and why companies enter merger ...
... Oct. 7 Sunridge International (OTC Bulletin Board: ... Trabeculoplasty (PNT) non-invasive treatment for glaucoma and ocular hypertension, ... by Beijing Vision World Trading Co. Ltd. (BVW), in ... patient research studies before gaining regulatory approval by China,s ...
Cached Medicine Technology:Reportlinker Adds Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics, 4th edition 2Reportlinker Adds Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics, 4th edition 3Reportlinker Adds Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics, 4th edition 4Reportlinker Adds Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics, 4th edition 5Reportlinker Adds Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics, 4th edition 6Reportlinker Adds Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics, 4th edition 7Reportlinker Adds Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics, 4th edition 8Sunridge Advances its PNT Glaucoma Treatment Throughout China 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: